Genome Insight has launched its whole-genome sequencing (WGS) test, CancerVision, in the US.

The test has been developed to offer precise, timely, and medically relevant information that assists in making individualised healthcare decisions.

CancerVision integrates advanced bioinformatics and computational-sequencing techniques to determine whole-genome mutational profiles of individual cancer patients.

These profiles will be analysed and curated in a user-friendly format for physicians to implement relevant and actionable insights.

According to the company, the test helps find genetic variations, including point mutations, structural variations and gene fusions, associated with FDA-approved treatments.

It offers additional genomic findings linked to personalised treatment approaches, as well as helps in engaging suitable clinical studies to assist with future steps.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CancerVision also provides complete access to tumour mutational burden and mutational signature and inherited germline polymorphisms to improve the decision-making process.

Following the presentation of data at the American Association of Cancer Research 2023 annual meeting, the company launched CancerVision in the US.

The data revealed that the test demonstrated a more thorough analysis of specific genetic mutations in breast cancers compared to traditional BRCA gene testing.

Genome Insight and Ultima Genomics have joined forces to make WGS affordable for cancer patients.

To achieve this, both entities intend to combine Ultima Genomics’ low-cost sequencing with Genome Insight’s bioinformatics platform.

Genome Insight CEO Jehee Suh said: “We are an organisation of medical doctors with computational know-how that enables us to harness this incredibly important data for real-time, real-world application for cancer patients and beyond.

“Our goal is to sequence genomic data for one million cancer patients, progressing our understanding of cancer for improved patient outcomes.”

Furthermore, the company announced the opening of its corporate headquarters in San Diego, California.